Medicure Inc (OTC:MCUJF)

Monday, December 5, 2016 | Web News
MCUJF ($6.61) - Shares of Canadian pharmaceutical company MCUJF have jumped to new highs on the heels of closing the acquisition of Apicore....
Monday, January 11, 2016 | Web News
WINNIPEG, Jan. 11, 2016 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:...
Tuesday, November 10, 2015 | Web News
Third Quarter 2015 Results Recorded net revenue of $5.4 million during the quarter ended September 30, 2015, an increase of 155% compared...
See All Research...
Medicure Inc., a biopharmaceutical company, researches, develops, and commercializes human therapeutics in Canada, the United States, and Barbados. The company markets and sells AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It is also developing Tardoxal, which is in Phase IIa clinical trial for the treatment of tardive dyskinesia/neurological indications; and Transdermal AGGRASTAT that is in a preclinical stage for acute cardiology. In addition, the company offers novel therapeutics comprising a series of small molecule dual acting anticoagulant/antiplatelet compounds to treat venous and arterial thrombosis. Medicure Inc. was founded in 1997 and is headquartered in Winnipeg, Canada.

Web site: http:// http://www.medicure.com

Last updated April 8, 2014


Market Data powered by QuoteMedia. Terms of Use